Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Phase 3 Completed Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety of desvenlafaxine sustained release (DVS-233SR) during open-label treatment of outpatients with major depressive disorder (MDD).

Timeline

Start: 2004-01
Primary completion: —
Completion: 2005-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desvenlafaxine	Other / unclassified	—	—

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Summary

Timeline

Drugs

Indications